Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01217190
Other study ID # OND/CR/020/08-09
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 16, 2008
Est. completion date October 6, 2008

Study information

Verified date July 2020
Source Aquestive Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.


Description:

This was an open label, balanced, randomized, two-treatment, two-period, randomized sequence crossover study conducted in healthy adult male and female volunteers. Subjects checked into the study center on Day -1 of each study period at least 12 hours prior to dosing on Day 1. Subjects were served dinner between 8:00 pm to 8:30 pm to ensure minimum 10 hours fast prior to dosing in both periods. Subjects received the 2 treatments in a randomized order with a 7-day washout between the 2 periods.

Treatment A: single dose of ondansetron ODFS 8 mg was orally administered, allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature drinking water

Treatment B: single dose of Zofran ODT (containing ondansetron 8 mg) was orally administered, allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature drinking water


Other known NCT identifiers
  • NCT01216969

Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date October 6, 2008
Est. primary completion date September 26, 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Volunteer should have written informed consent.

- Volunteer healthy adult within 18-45 years of age (inclusive).

- Body mass index of 18.5 kg/m^2 and 25 kg/m^2, body weight not less than 50 kg.

- Volunteer must be of normal health.

- Volunteer should have a normal ECG, chest X-ray and vital signs.

- If study volunteer is a female and is of child bearing potential practicing an acceptable method of birth control for the duration of the study.

Criteria: Exclusion Criteria:

- Volunteer doesn't understand the informed consent.

- Volunteer with a history of hypersensitivity or idiosyncratic reaction to study drug or any other related drug.

- Volunteer having any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function, by standard laboratory, imaging or monitoring procedures

- Volunteer who smokes regularly, alcohol or drug abuse

- Volunteer who has taken over the counter or prescribed medications

- Volunteer with clinically significant abnormal values of laboratory parameters.

- Volunteer who has participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.

- Female volunteer demonstrating a positive pregnancy screen with urine pregnancy test (strip method).

Study Design


Related Conditions & MeSH terms

  • Nausea
  • Nausea and Vomiting, Postoperative
  • Nausea With Vomiting Chemotherapy-Induced
  • Postoperative Nausea and Vomiting
  • Vomiting

Intervention

Drug:
Ondansetron (ODFS)
Test Article
Zofran (ODT)
Comparator

Locations

Country Name City State
India VIMTA VHS Research Centre Adyar Chennai

Sponsors (1)

Lead Sponsor Collaborator
MonoSol Rx

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Maximum Plasma Concentration occurring at Tmax (Time to reach maximum concentration) 0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours
Primary AUCt Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration 0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours
Primary AUCinf Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity 0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06302673 - The Role Of Laserpuncture For Prevention Of Nausea And Vomiting Post Strabismus Surgery With General Anesthesia In Adult Patients N/A
Recruiting NCT04563494 - The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain Phase 4
Completed NCT00108095 - A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting Phase 2
Not yet recruiting NCT05426278 - The Effect Of Intraoperative Forced Air Warmer Use, On Postoperative Nausea And Vomiting N/A
Withdrawn NCT04954365 - Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
Not yet recruiting NCT06356623 - A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
Withdrawn NCT05016076 - Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial N/A
Not yet recruiting NCT04899817 - Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy Phase 4
Recruiting NCT05875077 - Propofol Versus Dexmedetomidine on the Incidence of Postoperative Nausea and Vomiting N/A
Completed NCT03338400 - Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role? Phase 2
Completed NCT05692245 - Dexamethasone vs Ondansetron After Cesarean Delivery Phase 4
Completed NCT03125941 - High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Phase 4
Completed NCT00326248 - Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women Phase 3
Completed NCT00334152 - Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women Phase 3
Recruiting NCT03586817 - PALONOSETRON X FOSAPREPITANT IN PONV Phase 4
Not yet recruiting NCT06357234 - Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Phase 2
Completed NCT03045133 - QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE Phase 4
Not yet recruiting NCT06410365 - Impact of Intrathecal vs Intravenous Dexmedetomidine Phase 4
Recruiting NCT05474001 - Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia N/A
Enrolling by invitation NCT05439798 - Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting Phase 3